THE BUILDERS / COMPANY RESEARCH
Moderna
Develops mRNA medicines and individualized neoantigen therapy with Merck.
Revenue history & outlook
Consolidated annual company revenue; all business lines, not AI-only sales. · USD billion
| Period | Revenue | Classification | Published | Source |
|---|---|---|---|---|
| FY2021 · ended Dec 31, 2021 | ≈18.47 | Reported observation | 2026-09-03 | Stock Analysis / S&P Global |
| FY2022 · ended Dec 31, 2022 | ≈19.26 | Reported observation | 2026-09-03 | Stock Analysis / S&P Global |
| FY2023 · ended Dec 31, 2023 | ≈6.85 | Reported observation | 2026-09-03 | Stock Analysis / S&P Global |
| FY2024 · ended Dec 31, 2024 | ≈3.24 | Reported observation | 2026-09-03 | Stock Analysis / S&P Global |
| FY2025 · ended Dec 31, 2025 | ≈1.94 | Reported observation | 2026-09-03 | Stock Analysis / S&P Global |
| FY2026 · analyst consensus | ≈2.1 | Independent projection | 2026-09-03 | Stock Analysis / S&P Global |
| FY2027 · analyst consensus | ≈2.44 | Independent projection | 2026-09-03 | Stock Analysis / S&P Global |